Welcome to our dedicated page for Tenaya Therapeutics SEC filings (Ticker: TNYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tenaya Therapeutics filings document a clinical-stage biotechnology issuer focused on genetic and small-molecule approaches to heart disease. Recent 8-K reports furnish operating results and corporate updates tied to TN-201, TN-401 and TN-301, including clinical and regulatory disclosures for cardiomyopathy programs and research updates for cardiovascular target validation.
The company’s SEC record also includes definitive proxy materials for annual-meeting governance and shareholder voting matters, material-agreement disclosure for its cardiovascular target research collaboration, capital-structure information and Nasdaq continued-listing compliance disclosures. These filings frame Tenaya’s public reporting around pipeline development, financing capacity, governance and common stock status.
Ali Faraz reported open-market sale transactions in a Form 4 filing for TNYA. The filing lists transactions totaling 14,862 shares at a weighted average price of $0.64 per share. Following the reported transactions, holdings were 452,415 shares.
Tingley Whittemore reported open-market sale transactions in a Form 4 filing for TNYA. The filing lists transactions totaling 5,160 shares at a weighted average price of $0.64 per share. Following the reported transactions, holdings were 222,136 shares.
TNYA filed a Form 144 notice for a planned stock sale. The filing covers the proposed sale of 14,862 shares of common stock on or about February 17, 2026 through Morgan Stanley Smith Barney, with an aggregate market value of $9,556.66.
The issuer had 213,744,535 shares outstanding at the time referenced. The securities to be sold stem from a restricted stock unit acquisition of 39,688 common shares from the issuer on February 17, 2026. The signer represents they are not aware of undisclosed material adverse information about the company.
A shareholder filed a notice to sell 5,160 shares of common stock under Rule 144 through Morgan Stanley Smith Barney on or about February 17, 2026. The shares have an aggregate market value of $3,318.72 and are listed on the Nasdaq Global Select Market.
The securities relate to common stock acquired on February 17, 2026 via a restricted stock unit grant from the issuer, totaling 13,750 shares. The issuer reports 213,744,535 shares of this class outstanding, providing context for the size of the planned sale.
The Column Group–affiliated funds filed Amendment No. 6 to their Schedule 13D on Tenaya Therapeutics, Inc. common stock. The filing updates ownership and reports that venture funds TCG III LP and TCG III-A LP sold shares on February 10–11, 2026 at weighted-average prices of $0.8161 and $0.6808 per share.
After these sales, various Column Group entities report beneficial ownership of up to 54,313,559 shares each for Tim Kutzkey and Peter Svennilson, representing 25.4% of Tenaya’s common stock, based on 213,744,535 shares outstanding as of December 15, 2025. The filing also notes excluded warrants to purchase 53,571,426 additional shares that are not exercisable within 60 days due to Beneficial Ownership Limitations.
Tenaya Therapeutics major shareholder funds affiliated with The Column Group reported open-market sales of common stock.
On February 10, 2026, The Column Group III, LP and The Column Group III-A, LP reported selling 161,422 and 182,295 Tenaya Therapeutics shares, respectively, at a weighted average price of $0.8161, with individual trades between $0.80 and $0.84.
On February 11, 2026, affiliated funds reported additional sales of 1,905,115 and 2,151,458 shares at a weighted average price of $0.6808, with trades between $0.65 and $0.80. After these transactions, one affiliated fund reported indirectly holding 49,313,559 Tenaya shares.
Column Group III-A, LP filed a notice of proposed sale under Rule 144 to sell 742,663 shares of Tenaya Therapeutics common stock through BTIG, LLC on NASDAQ, with an aggregate market value of $504,788.00 and an approximate sale date of February 11, 2026.
The shares were originally acquired for cash in a Series A financing on July 31, 2017. Over the past three months, Column Group III-A, LP has already sold 182,295 Tenaya common shares for $148,770.95. Tenaya had 213,744,535 common shares outstanding at the time referenced.
Tenaya Therapeutics shareholder Column Group III, LP has filed to sell up to 657,627 shares of common stock under Rule 144. The planned sale is to be executed through BTIG, LLC on NASDAQ, with an approximate sale date of 02/11/2026 and an aggregate market value of $446,989.00.
The shares were originally acquired on 07/31/2017 in a Series A financing for cash. Column Group III, LP also sold 161,422 Tenaya common shares on 02/10/2026 for gross proceeds of $131,736.49. Shares outstanding were 213,744,535 common shares at the time referenced.
Tenaya Therapeutics, Inc. (TNYA) shareholder has filed a notice of proposed sale under Rule 144 for 1,591,090 shares of common stock. The shares are to be sold through BTIG, LLC on or around February 10, 2026 on the NASDAQ.
The filing lists an aggregate market value of $1,256,960.80 for the proposed sale and notes that 213,744,535 shares of common stock were outstanding. The shares being sold were originally acquired in Series A financing transactions in 2016 and 2017 for cash.
A Tenaya Therapeutics stockholder filed a notice of proposed sale of 1,408,910 common shares under Rule 144. The shares have an aggregate market value of $1,113,038.00, with an approximate sale date of February 10, 2026 on the NASDAQ exchange.
The seller previously acquired these common shares in Series A financing transactions from Tenaya Therapeutics on October 13, 2016 and July 31, 2017, paying the purchase price in cash. The person signing the notice represents that they are not aware of undisclosed material adverse information about Tenaya’s operations.